New studies in vitro antibacterial evaluation and cell viability in PMMA-G-PEG 4000 derivatives with encapsulated Erythromycin.
dc.contributor.author | Azevedo, Maria Luíza Schaefer | |
dc.contributor.author | Rezende, Giselle A. S. | |
dc.contributor.author | Sousa, Lucas Resende Dutra | |
dc.contributor.author | Reis, Rúbia Castro Fernandes Melo | |
dc.contributor.author | Novack, Kátia Monteiro | |
dc.contributor.author | Barboza, Ana Paula Moreira | |
dc.contributor.author | Neves, Bernardo Ruegger Almeida | |
dc.contributor.author | Amparo, Tatiane Roquete | |
dc.contributor.author | Teixeira, Luiz Fernando de Medeiros | |
dc.contributor.author | Vieira, Paula Melo de Abreu | |
dc.contributor.author | Perasoli, Fernanda Barçante | |
dc.contributor.author | Santos, Viviane Martins Rebello dos | |
dc.date.accessioned | 2023-01-26T19:09:44Z | |
dc.date.available | 2023-01-26T19:09:44Z | |
dc.date.issued | 2022 | pt_BR |
dc.description.abstract | Synthetic polymers have been extensively studied in several areas of knowledge, one of which is the pharmaceutical. The drug when encapsultated into the PMMA-g-PEG 4000 matrix can produce fewer side effects. The most frequent side effects of erythromycin are gastrointestinal and are dose related. Nausea, vomiting and diarrhea occur in low frequency with the usual oral doses. The drug used in this study was Erythromycin, an antimicrobial that acts directly on bacterial protein synthesis. Erythromycin was encapsulated into PMMA-g-PEG 4000 derivatives. All copolymers afther encapsultaions were characterized and identified by atomic force microscopy (AFM). In vitro assays of release, antimicrobial activity and cytotoxicity were performed for the copolymers obtained. The copolymers PMMA-g-PEG 4000 HAL and PMMA-g-PEG 4000 ACET showed drug controlled release profiles. All PMMA-g-PEG 4000 derivatives showed antibacterial activity against Staphylococcus aureus and did not show a cytotoxic effect on human fibroblasts. | pt_BR |
dc.identifier.citation | AZEVEDO, M. L. S. et al. New studies in vitro antibacterial evaluation and cell viability in PMMA-G-PEG 4000 derivatives with encapsulated Erythromycin. Revista Virtual de Quimica, v. 14, n. 5, p. 814-818, 2022. Disponível em: <https://rvq-sub.sbq.org.br/index.php/rvq/article/view/4267>. Acesso em: 11 out. 2022. | pt_BR |
dc.identifier.doi | https://doi.org/10.21577/1984-6835.20220037 | pt_BR |
dc.identifier.issn | 1984-6835 | |
dc.identifier.uri | http://www.repositorio.ufop.br/jspui/handle/123456789/16054 | |
dc.language.iso | en_US | pt_BR |
dc.rights | aberto | pt_BR |
dc.rights.license | This is an open-access article distributed under the terms of the Creative Commons Attribution License. Fonte: o PDF do artigo. | pt_BR |
dc.subject | Copolymers | pt_BR |
dc.subject | Controlled release | pt_BR |
dc.subject | Antibacterial activity | pt_BR |
dc.title | New studies in vitro antibacterial evaluation and cell viability in PMMA-G-PEG 4000 derivatives with encapsulated Erythromycin. | pt_BR |
dc.title.alternative | Novos estudos de avaliação antibacteriana in vitro e viabilidade celular em PMMA-G-PEG 4000 derivados com Eritromicina encapsulada. | pt_BR |
dc.type | Artigo publicado em periodico | pt_BR |
Arquivos
Pacote Original
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- ARTIGO_NewStudiesVitro.pdf
- Tamanho:
- 1.23 MB
- Formato:
- Adobe Portable Document Format
- Descrição:
Licença do Pacote
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descrição: